Clinical trial
Efficacy and Safety of Sintilimab in Combination With Platinum-containing Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma: a Prospective, Open, Single-arm, Single-center Clinical Study
NCT06563869 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Sintilimab in Combination With Platinum-containing Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma: a Prospective, Open, Single-arm, Single-center Clinical Study
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- February 2, 2024
- Completion date
- November 22, 2026
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.